Article- Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learned a year in


Authors: Maura Pugliatti1,2, Hans-Peter Hartung3,4,5, Celia Oreja-Guevara6,7, Carlo Pozzilli8, Laura Airas9,10, Mona Alkhawajah11,12, Nikolaos Grigoriadis13, Melinda Magyari14, Bart Van Wijmeersch15,16,17, Magd Zakaria18, Ralf Linker19, Andrew Chan20, Patrick Vermersch21 and Thomas Berger22,23

1Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy, 2Interdepartmental Center of Research for Multiple Sclerosis and Neuro-inflammatory and Degenerative Diseases, University of Ferrara, Ferrara, Italy, 3Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, 4Brain and Mind Center, University of Sydney, Sydney, NSW, Australia, 5Department of Neurology, Palacky University Olomouc, Olomouc, Czechia, 6Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain, 7Faculty of Medicine, Complutense University of Madrid (UCM), Madrid, Spain, 8Multiple Sclerosis Center, S. Andrea Hospital, Department of Human Neuroscience, University Sapienza, Rome, Italy, 9Division of Clinical Neurosciences, University of Turku, Turku, Finland, 10Neurocenter of Turku University Hospital, Turku, Finland, 11Section of Neurology, Neurosciences Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 12College of Medicine, Al Faisal University, Riyadh, Saudi Arabia, 13Laboratory of Experimental Neurology and Neuroimmunology, Second Department of Neurology, American Hellenic Educational Progressive Association (AHEPA) University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, 14Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 15Universitair Multiple Sclerosis (MS) Centrum, Hasselt-Pelt, Belgium, 16Revalidatie & Multiple Sclerosis (MS), Noorderhart, Pelt, Belgium, 17Rehabilitation Research Center (REVAL) & Biomedical Research Institute (BIOMED), Hasselt University, Hasselt, Belgium, 18Department of Neurology, Ain Shams University, Cairo, Egypt, 19Clinic and Polyclinic for Neurology, Universitätsklinikum Regensburg, Regensburg, Germany, 20Department of Neurology, Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland, 21University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, 22Department of Neurology, Medical University of Vienna, Vienna, Austria, 23Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria


Abstract

It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.



Media

Details

  • Directors

    ParadigMS
  • Author(s)

    Prof Maura Pugliatti, Prof Hans-Peter Hartung, Prof Celia Oreja-Guevara, Prof Carlo Pozzilli, Prof Laura Airas, Prof Mona Alkhawajah, Prof Nikolaos Grigoriadis, Prof Melinda Magyari, Prof Bart Van Wijmeersch, Prof Magd Zakaria, Prof Ralf Linker, Prof Andrew Chan, Prof Patrick Vermersch, Prof Thomas Berger
  • Country

  • Release Date

    October 17, 2022
  • Views


Educational slide decks
endorsed by experts

Minimum two MS experts collaborate to produce an educational slide deck. These slide decks are presented (live) to ParadigMS members, peer reviewed and updated.
The slide decks are published on the ParadigMS website “on behalf of ParadigMS”.

Consensus publications

Based on the slide decks, publications are produced. These publications are peer reviewed and published as consensus publications.

Regional and national educational events

Regional (fe: Scandinavian countries, Benelux, …) or national events where state-of-the-art science is transferred to general neurologists and other care givers (nurses, etc) that are confronted with MS in their day to day practice.

Web-based educational tools and resources

Webinars can complement the educational events.

Medical education (ME) programs

The educational slide decks, events and webinars can be important building blocks of accredited educational programs.

FAQs

Do subscriptions auto-renew?
Your subscription will automatically renew on a monthly or yearly basis, depending on the plan you have chosen. If you cancel your plan, it will not renew at the end of your subscription cycle. It will end once the period you have paid for is over.
What happens if I subscribe as a healthcare practitioner if I am not a healthcare practitioner?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, you will be banned immediately from the community and could be liable to prosecution.
How can I cancel my trial or subscription?
You can cancel your trial or subscription in your account settings. If you cancel during the trial period you will not be charged.

Terms and Conditions

All the Terms and Conditions of the ParadigMS Foundation Website can be downloaded here.

Subscribe to our bi-annual Newsletter

ParadigMS does not send eNewsletters that contain advertisements and we do not share your contact details with sponsors (unless we received your explicit consent)